It’s time to take the first step: to have a conversation with your doctor about the changes you’ve been experiencing, how your health is being affected, and whether these signs and symptoms could be ...
Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.
It’s time to take the first step: to have a conversation with your doctor about the changes you’ve been experiencing, how your health is being affected, and whether these signs and symptoms could be ...
Changes associated with the disease were found in multiple molecules in the blood of people with lupus. The changes resulted in insufficient activation of a pathway that the aryl hydrocarbon ...
Lupus nephritis is an inflammatory kidney disease ... Dörner and Lipsky discuss the potential of targeting these pathways to eliminate autoreactive memory B cells and plasma cells in SLE.
Systemic lupus erythematosus is a potentially fatal ... Dörner and Lipsky discuss the potential of targeting these pathways to eliminate autoreactive memory B cells and plasma cells in SLE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback